Kidney Week

Abstract: SA-PO947

Association of Anti-EPOR Antibodies with Clinicopathological Findings in Patients with IgA Nephropathy

Session Information

• Glomerular Diseases: Translational Studies and Biomarkers
  November 04, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

• Kajikawa, Sho, Kanazawa Daigaku Fuzoku Byoin Jinzo Naika, Kanazawa, Ishikawa, Japan

Sho Kajikawa,

• Oshima, Megumi, Kanazawa Daigaku Fuzoku Byoin Jinzo Naika, Kanazawa, Ishikawa, Japan

Megumi Oshima,

• Horikoshi, Keisuke, Kanazawa Daigaku Fuzoku Byoin Jinzo Naika, Kanazawa, Ishikawa, Japan

Keisuke Horikoshi,

• Sako, Keisuke, Kanazawa Daigaku Fuzoku Byoin Jinzo Naika, Kanazawa, Ishikawa, Japan

Keisuke Sako,

• Yuasa, Takahiro, Kanazawa Daigaku Fuzoku Byoin Jinzo Naika, Kanazawa, Ishikawa, Japan

Takahiro Yuasa,

• Minami, Taichiro, Kanazawa Daigaku Fuzoku Byoin Jinzo Naika, Kanazawa, Ishikawa, Japan

Taichiro Minami,

• Nakagawa, Shiori, Kanazawa Daigaku Fuzoku Byoin Jinzo Naika, Kanazawa, Ishikawa, Japan

Shiori Nakagawa,

• Toyama, Tadashi, Kanazawa Daigaku Fuzoku Byoin Jinzo Naika, Kanazawa, Ishikawa, Japan

Tadashi Toyama,

• Kitajima, Shinji, Kanazawa Daigaku Fuzoku Byoin Jinzo Naika, Kanazawa, Ishikawa, Japan

Shinji Kitajima,

• Hara, Akinori, Kanazawa Daigaku Fuzoku Byoin Jinzo Naika, Kanazawa, Ishikawa, Japan

Akinori Hara,

• Iwata, Yasunori, Kanazawa Daigaku Fuzoku Byoin Jinzo Naika, Kanazawa, Ishikawa, Japan

Yasunori Iwata,

• Sakai, Norihiko, Kanazawa Daigaku Fuzoku Byoin Jinzo Naika, Kanazawa, Ishikawa, Japan

Norihiko Sakai,

• Shimizu, Miho, Kanazawa Daigaku Fuzoku Byoin Jinzo Naika, Kanazawa, Ishikawa, Japan

Miho Shimizu,

• Wada, Takashi, Kanazawa Daigaku Fuzoku Byoin Jinzo Naika, Kanazawa, Ishikawa, Japan

Takashi Wada,

Background

Disease severity in immunoglobulin A nephropathy (IgAN) is mainly determined by pathological findings. Noninvasive and more convenient biomarkers are thus required for evaluating its activity. In previous studies, the presence of autoantibodies to the erythropoietin receptor (anti-EPOR antibodies) has been shown to be associated with high disease activity and kidney function decline in patients with various kidney diseases including lupus nephritis, type 2 diabetes, and anti-neutrophil cytoplasmic antibody-associated vasculitis. In this study, we therefore investigated the association of anti-EPOR antibodies with clinical and pathological findings in patients with IgAN.

Methods

This retrospective cohort study included 56 patients with biopsy-proven IgAN between 2006 and 2016 at Kanazawa University Hospital. Serum anti-EPOR antibodies at kidney biopsy were measured by using enzyme-linked immunosorbent assays. We then evaluated the associations of anti-EPOR antibodies with clinical and pathological characteristics.

Results

The presence of anti-EPOR antibodies was detected in 12 (21%) patients. Mean age, eGFR, and hemoglobin were comparable at baseline between the patients with and without anti-EPOR antibodies. Serum IgA/C3 ratio was higher in patients with anti-EPOR antibodies than those without (4.33 versus 3.19, p = 0.001). For pathological findings, patients with anti-EPOR antibodies were more likely to have active glomerular lesions, such as crescents or adhesions, compared to those without (91.7% versus 66.7%). During mean follow-up of 7.6 years, no statistical differences were found in annual eGFR declines between the patients with and without anti-EPOR antibodies (Mean±SD: 1.4±3.8 vs. 3.0±3.8 ml/min/1.73 m²/year).

Conclusion

The presence of anti-EPOR antibodies may reflect disease activity in patients with IgAN.

Funding

• Government Support – Non-U.S.